Paper41228299
Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer.
Safa A and 3 others. Cancers (Basel), 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer. Papers, record 41228299. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41228299
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Italian Ministry of Health (Ricerca Corrente) | Italian Ministry of Health (Ricerca Corrente) | PubMed |
Source PubMed
References250
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34267656 | Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34267656 | PubMed |
| 2 | 15937340 | Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15937340 | PubMed |
| 3 | 39752908 | ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. | Transl Oncol | 2025 | https://conductscience.org/library/papers/39752908 | PubMed |
| 4 | 39043656 | The molecular basis underlying T cell specificity towards citrullinated epitopes presented by HLA-DR4. | Nat Commun | 2024 | https://conductscience.org/library/papers/39043656 | PubMed |
| 5 | 37346044 | Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells. | Front Immunol | 2023 | https://conductscience.org/library/papers/37346044 | PubMed |
| 6 | 34106045 | Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. | Elife | 2021 | https://conductscience.org/library/papers/34106045 | PubMed |
| 7 | 24605112 | The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. | Front Immunol | 2014 | https://conductscience.org/library/papers/24605112 | PubMed |
| 8 | 37643018 | ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. | JCI Insight | 2023 | https://conductscience.org/library/papers/37643018 | PubMed |
| 9 | 37500632 | MSBooster: improving peptide identification rates using deep learning-based features. | Nat Commun | 2023 | https://conductscience.org/library/papers/37500632 | PubMed |
| 10 | 36365233 | PAD4 and Its Inhibitors in Cancer Progression and Prognosis. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36365233 | PubMed |
| 11 | 36612133 | Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36612133 | PubMed |
| 12 | 37550801 | ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. | J Pathol | 2023 | https://conductscience.org/library/papers/37550801 | PubMed |
| 13 | 32226930 | Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. | Chronic Dis Transl Med | 2020 | https://conductscience.org/library/papers/32226930 | PubMed |
| 14 | 35533046 | Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. | J Pathol | 2022 | https://conductscience.org/library/papers/35533046 | PubMed |
| 15 | 36104770 | O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. | Mol Med | 2022 | https://conductscience.org/library/papers/36104770 | PubMed |
| 16 | 36543135 | β-hydroxybutyrate inhibits ferroptosis-mediated pancreatic damage in acute liver failure through the increase of H3K9bhb. | Cell Rep | 2022 | https://conductscience.org/library/papers/36543135 | PubMed |
| 17 | 37143582 | Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. | MedComm (2020) | 2023 | https://conductscience.org/library/papers/37143582 | PubMed |
| 18 | 40790272 | Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. | Nat Med | 2025 | https://conductscience.org/library/papers/40790272 | PubMed |
| 19 | 37353482 | Molecular mechanism of phosphopeptide neoantigen immunogenicity. | Nat Commun | 2023 | https://conductscience.org/library/papers/37353482 | PubMed |
| 20 | 35626033 | Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35626033 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42983511 | Pan-modification proteomics: decoding tumor heterogeneity and guiding the next generation of precision oncology. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42983511 | PubMed |
| 42681683 | Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer. | Biomark Res | 2026 | https://conductscience.org/library/papers/42681683 | PubMed |
| 42657027 | Phosphorylation shapes antigen presentation and immune recognition: mechanistic insights and translational perspectives. | Front Immunol | 2026 | https://conductscience.org/library/papers/42657027 | PubMed |
| 42507221 | Rewiring glucose metabolism in pancreatic cancer by natural compounds: implications for immune evasion and therapeutic targets. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42507221 | PubMed |
| 42375394 | Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42375394 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| OGT | 8473 | PubTator's text mining | https://conductscience.org/library/genes/8473 | NCBI Gene |
| PADI4 | 23569 | PubTator's text mining | https://conductscience.org/library/genes/23569 | NCBI Gene |
| ST6GAL1 | 6480 | PubTator's text mining | https://conductscience.org/library/genes/6480 | NCBI Gene |
| TRBV20OR9-2 | 6962 | PubTator's text mining | https://conductscience.org/library/genes/6962 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41228299
GET https://conductscience.org/api/papers/v1/41228299/references?page=2